Palimpsest Bio Corp. — SEC Form D Filing
Palimpsest Bio Corp. filed an SEC Form D on October 30, 2026, reporting $172K raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 30, 2026
- Amount reported
- $172K
- Round stage
- Pre-seed phase given the preliminary $172,000 capital raised via a SAFE instrument to initiate foundational drug discovery operations.
- Industry
- Biotechnology
- Website
- https://palimpsest.bio
What the company does
Securities: Simple Agreement for Future Equity (SAFE). Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Traditional drug discovery pipelines suffer from low clinical success rates due to inadequate biological target validation and complex data processing limitations.
Solution
Palimpsest Bio develops proprietary biological discovery technologies to identify and validate novel therapeutic targets for complex diseases.
Why now
Advances in high-throughput biological screening and data analytics now enable early-stage biotechnology platforms to decode complex cellular mechanisms with minimal initial capital.
Verdict
At $172,000, this was an exploratory angel check rather than a capitalized institutional round. This cleared because early backers bought cheap optionality on an early molecular control hypothesis, not because Palimpsest demonstrated a proprietary wet-lab moat or verified pharma demand. Investors implicitly bet that a minimal proof-of-concept could be achieved on personal or incubator balance sheets. However, the micro-raise severely limits durability, leaving the company instantly exposed to dilution and execution stalls in a therapeutic category where venture-backed peers deploy tens of millions to generate baseline pre-clinical validation.
Source: SEC EDGAR Form D filing